Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PARL | Q9H300 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13353686 | 0.88 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL16912993 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL1519692 | 0.85 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL13353683 | 0.83 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL25332920 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL7485956 | 0.82 | ALDH1A1 (0.79) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL21681941 | 0.82 | ALDH1A1 (0.74) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL12386396 | 0.81 | KDM4E (0.71) | SMN1; SMN2ALDH1A1LMNAHTTRECQL | |
| SCHEMBL1269605 | 0.80 | ALDH1A1 (0.82) | SMN1; SMN2ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL3691866 | 0.80 | ALDH1A1 (0.82) | SMN1; SMN2ALDH1A1LMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | SMN1; SMN2 664/4885ALDH1A1 2105/4885LMNA 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.